33
Participants
Start Date
August 31, 2011
Primary Completion Date
July 10, 2019
Study Completion Date
July 10, 2019
Rituximab
R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
Prophylactic intrathecal chemotherapy
Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
Chonbuk National University Hospital, Jeonju
Consortium for Improving Survival of Lymphoma
OTHER
Chonbuk National University Hospital
OTHER